Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment (Q37159329)

18 August 2017

1 reference

title

Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment (English)

1 reference

18 August 2017

0 references

arterial hypertension

0 references

pathophysiology

1 reference

inferred from title

pulmonary hypertension

1 reference

Raymond L Benza

1

1 reference

18 August 2017

10 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

186

1 reference

18 August 2017

4

1 reference

18 August 2017

247-254

1 reference

https://scigraph.springernature.com/pub.10.1007/s00408-008-9092-8

18 August 2017

0 references

cites work

Clinical classification of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary arterial hypertension: the key role of echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pathophysiology of stroke in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension in patients with sickle cell disease: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role for L-carnitine treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Increased pulmonary artery pressures among adolescents with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Heart disease in thalassemia intermedia: a review of the underlying pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Plasma natriuretic peptide levels and the risk of cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Endothelin-receptor antagonists in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Nitric oxide therapy in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension in sickle cell disease: relevance to children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Endothelin-1 in Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Endothelin-1 Production during the Acute Chest Syndrome in Sickle Cell Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-008-9092-8

Increased levels of endothelin-1 in plasma of sickle cell anemia patients

21 January 2018

1 reference

12 December 2020

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

12 December 2020

Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

1 reference

12 December 2020

Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.

1 reference

12 December 2020

Clinical hemoglobinopathies: iron, lungs and new blood

1 reference

12 December 2020

Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation

1 reference

12 December 2020

Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies.

1 reference

12 December 2020

Modulation of Gardos channel activity by cytokines in sickle erythrocytes

1 reference

12 December 2020

Endothelial cells in physiology and in the pathophysiology of vascular disorders

1 reference

12 December 2020

Pulmonary hypertension in patients with hemoglobinopathies: could a mechanism for dysfunction provide an avenue for novel therapeutics?

1 reference

12 December 2020

Clinical differences between children and adults with pulmonary hypertension and sickle cell disease

1 reference

12 December 2020

High prevalence of pulmonary hypertension in children with sickle cell disease

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S00408-008-9092-8

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18470553